{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:49:07Z","timestamp":1761094147873,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.bbmt.2015.07.011","type":"journal-article","created":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T22:00:39Z","timestamp":1436824839000},"page":"1856-1857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Models of Therapy: When Acute Leukemia Becomes\u00a0Chronic"],"prefix":"10.1016","volume":"21","author":[{"given":"Celalettin","family":"Ustun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.07.011_bib1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.leukres.2008.09.027","article-title":"Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V","volume":"33","author":"Ustun","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2015.07.011_bib2","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.3324\/haematol.2014.109975","article-title":"Use of sorafenib for post-transplant relapse in FLT3\/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect","volume":"99","author":"Liegel","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2015.07.011_bib3","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.07.011_bib4","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/leu.2012.105","article-title":"High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses","volume":"26","author":"Metzelder","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.07.011_bib5","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.07.011_bib6","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.07.011_bib7","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.bbmt.2014.02.020","article-title":"Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a Center for International Blood and Marrow Transplant Research-Eurocord analysis","volume":"20","author":"Weisdorf","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.011_bib8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.07.011_bib9","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.bbmt.2014.09.007","article-title":"Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.011_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.clml.2014.12.005","article-title":"Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation","volume":"15","author":"Antar","year":"2015","journal-title":"Clin Lymph Myel Leuk"},{"key":"10.1016\/j.bbmt.2015.07.011_bib11","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.bbmt.2011.07.011","article-title":"Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib","volume":"17","author":"Sharma","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.011_bib12","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2015.07.011_bib13","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.bbmt.2011.12.587","article-title":"Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"18","author":"Caocci","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.07.011_bib14","doi-asserted-by":"crossref","DOI":"10.5858\/arpa.2014-0543-CP","article-title":"Marked variability in reported minimal residual disease lower level of detection of 4 hematolymphoid neoplasms: a survey of participants in the College of American Pathologists' flow cytometry proficiency testing program","author":"Keeney","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.bbmt.2015.07.011_bib15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cancergencyto.2007.05.017","article-title":"Relapsed acute myelogenous leukemia occurring after 18 years with recurrent novel chromosomal abnormality t(18;22)(q23;q11.2)","volume":"177","author":"Ustun","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.bbmt.2015.07.011_bib16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911500467X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108387911500467X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:51:38Z","timestamp":1761058298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108387911500467X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S108387911500467X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.011","relation":{},"ISSN":["1083-8791"],"issn-type":[{"type":"print","value":"1083-8791"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Models of Therapy: When Acute Leukemia Becomes\u00a0Chronic","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}